



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

TECH CENTER 1600/2900
AUG 29 2001

Nancy Malsich
Nancy Malsich

8/23/01
Date of Deposit

Applicant: Lee, et al.

Serial No.: 09/581,044

Filed: June 8, 2000

Title: HIV/FIV PROTEASE INHIBITORS
HAVING A SMALL P3 RESIDUE

Group Art Unit: 1653

Examiner: J. Russel

Our Ref.: TSRI 609.1

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT (37 CFR 1.121)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Responsive to the Notice of Non-Compliant Amendment (Paper Number 9) mailed July 23, 2001, submitted herewith is the clean version of the replacement sequence paragraphs with instructions for entry and the marked-up version of the replacement paragraphs as amended on June 19, 2001.

At page 12, line 14, please substitute the following paragraph for the previous version:

R1 Each compound tested in this study is a competitive inhibitor and is significantly more potent against HIV PR than FIV PR, as expected. However, the new inhibitors **1b-6b**, and **7a** showed a remarkable different pattern of inhibitory activities compared to their parent compounds **1a-5a**, ABT-538 and RO31-8959. Compounds **2a-4a**, containing no P3 moieties, exhibited marginal